Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-250-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.72 billion
Profitability
Miscellaneous
Employees12,800
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable
Edwards Lifesciences (NYSE:EW) Frequently Asked Questions
What is Edwards Lifesciences' stock symbol?
Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?
Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.
How will Edwards Lifesciences' stock buyback program work?
Edwards Lifesciences announced that its Board of Directors has authorized a stock repurchase plan on Thursday, December 7th 2017, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board believes its stock is undervalued.
How were Edwards Lifesciences' earnings last quarter?
Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $1.41 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.22 by $0.19. The medical research company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The firm's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period last year, the business earned $1.07 earnings per share. View Edwards Lifesciences' Earnings History.
When is Edwards Lifesciences' next earnings date?
What guidance has Edwards Lifesciences issued on next quarter's earnings?
Edwards Lifesciences issued an update on its FY19 earnings guidance on Wednesday, October, 23rd. The company provided EPS guidance of $5.50-5.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.34. The company issued revenue guidance of around top of $4-4.3 billion, compared to the consensus revenue estimate of $4.23 billion.
What price target have analysts set for EW?
18 brokers have issued twelve-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $159.00 to $265.00. On average, they anticipate Edwards Lifesciences' share price to reach $238.24 in the next twelve months. This suggests that the stock has a possible downside of 3.0%. View Analyst Price Targets for Edwards Lifesciences.
What is the consensus analysts' recommendation for Edwards Lifesciences?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.
What are Wall Street analysts saying about Edwards Lifesciences stock?
Here are some recent quotes from research analysts about Edwards Lifesciences stock:
- 1. According to Zacks Investment Research, "Edwards Lifesciences has reported better-than-expected second-quarter 2019 results. The company has been seeing strong TAVR sales globally. In the second quarter, it registered strong sales within Critical Care division, boosted by a surge in HemoSphere sales. With the full-market launch, the HemoSphere all-in-one monitoring platform has started to act as a major growth driver in 2019. The company is also upbeat about getting strong synergy benefit from the CASMED acquisition. Also, management looks forward to the CMS’ final update on national coverage determination related to TAVR programs. Overall, in the past three months, Edwards outperformed its industry. Meanwhile, persistent supply constraints dented Cardioband system sales. This apart, tough competition in the cardiac devices market and reimbursement issue pose concerns." (7/25/2019)
- 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019)
Has Edwards Lifesciences been receiving favorable news coverage?
News coverage about EW stock has trended very negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View News Stories for Edwards Lifesciences.
Are investors shorting Edwards Lifesciences?
Edwards Lifesciences saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,320,000 shares, a decrease of 15.9% from the September 30th total of 2,760,000 shares. Based on an average daily volume of 1,090,000 shares, the short-interest ratio is currently 2.1 days. Currently, 1.1% of the shares of the stock are short sold. View Edwards Lifesciences' Current Options Chain.
Who are some of Edwards Lifesciences' key competitors?
Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE), Varian Medical Systems (VAR) and Insulet (PODD).
What other stocks do shareholders of Edwards Lifesciences own?
Who are Edwards Lifesciences' key executives?
Edwards Lifesciences' management team includes the folowing people:
- Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
- Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
- Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
- Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
- Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer
Who are Edwards Lifesciences' major shareholders?
Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (0.72%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), CIBC Private Wealth Group LLC (0.35%), Railway Pension Investments Ltd (0.24%), California Public Employees Retirement System (0.22%) and Rhumbline Advisers (0.18%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.
Which institutional investors are selling Edwards Lifesciences stock?
EW stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Assenagon Asset Management S.A., Calamos Advisors LLC, First Trust Advisors LP, Country Trust Bank, SG Americas Securities LLC, Chicago Capital LLC and Robeco Institutional Asset Management B.V.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.
Which institutional investors are buying Edwards Lifesciences stock?
EW stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Sumitomo Mitsui Trust Holdings Inc., Columbus Circle Investors, Massachusetts Financial Services Co. MA, State of Tennessee Treasury Department, State of Alaska Department of Revenue and Abner Herrman & Brock LLC. View Insider Buying and Selling for Edwards Lifesciences.
How do I buy shares of Edwards Lifesciences?
Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Edwards Lifesciences' stock price today?
One share of EW stock can currently be purchased for approximately $245.64.
How big of a company is Edwards Lifesciences?
Edwards Lifesciences has a market capitalization of $51.23 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.
What is Edwards Lifesciences' official website?
How can I contact Edwards Lifesciences?
Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]
MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
